Findings of the BOREAS trial of patients with COPD and type 2 inflammation make dupilumab the first biologic to significantly reduce exacerbations by 30% vs placebo.
Rose McGowan
Advertisement
Articles by Rose McGowan
Advertisement
Latest Updated Articles
Dupilumab Reduces COPD Exacerbations for Patient with T2 Inflammation in Landmark Phase 3 TrialPublished: May 22nd 2023 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
This Year in Primary Care: 10 Critical Updates in 2025
2
FDA Approves Abbott Volt Pulsed Field Ablation System for Treatment of Atrial Fibrillation
3
Needle Anxiety and Injection Site Pain: Evidence-Based Strategies for Patient Counseling on Injectable PrEP
4